Fierce BioBiotech
UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine
21 Apr 20260 views
Summary
The agreement fulfills several ambitions for UCB. Besides building its epilepsy position, it "marks a strategic expansion into regenerative medicine and advanced therapies," the Belgian biopharma explained.
The agreement fulfills several ambitions for UCB. Besides building its epilepsy position, it "marks a strategic expansion into regenerative medicine and advanced therapies," the Belgian biopharma explained.